Recombinant Human IGF binding Protein 7/IGFBP-7 (C-6His)
|Amount :||50 µg|
|Content :||Lyophilized from a 0.2 µm filtered solution of PBS,pH7.4.|
|AA sequence :||Recombinant Human Insulin-like Growth Factor-binding Protein 7 is produced by our Mammalian expression system and the target gene encoding Ser27-Leu282 is expressed with a 6His tag at the C-terminus.|
|Alternative Name :||Insulin-like growth factor-binding protein 7;IGFBP7;IGF-binding protein 7;IGFBP-rP1;MAC25 protein;Tumor-derived adhesion factor;TAF|
Insulin-like growth factor-binding protein 7(IGFBP-7) is a secreted glycosylated protein that contains three protein domain modules. IGFBP7 contains an N-terminal IGFBP domain, followed by a Kazal-type serine proteinase inhibitor domain and a C-terminal immunoglobulin-like C2-type domain. Human and mouse IGFBP7 are highly homologous and share 94% aa sequence identity. It is expressed in many normal tissues and in cancer cells. It is abundantly expressed in high endothelial venules (HEVs) of blood vessels in the secondary lymphoid tissues. It binds IGF and insulin with very low affinity and has been shown to enhance the mitogenic actions of IGF and insulin. IGFBP7 also has IGF/insulin-independent activities. It interacts with heparan sulfate proteoglycans, type IV collagen, and specific chemokines. It supports weak cell adhesion, promotes cell spreading on type IV collagen, and stimulates the production of the potent vasodilator PGI2. It modulates tumor cell growth and has also been implicated in angiogenesis.